Twelves, Chris |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
| Recruiting | 2 | 60 | Europe | Ixabepilone Injection | Allarity Therapeutics, Allarity Therapeutics | Metastatic Breast Cancer | 10/24 | 11/25 | | |
| Recruiting | 1 | 158 | Europe, US | AVA6000 | Avacta Life Sciences Ltd | Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma | 03/26 | 08/26 | | |
Steg, Gabriel P |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Recruiting | 2 | 558 | Europe | Active arm 200 mg, Active arm 1000 mg, Placebo arm | Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France | ST Elevated Myocardial Infarction | 10/26 | 04/27 | | |
AI-ATTR-ECHO, NCT06328075: Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis |
|
|
| Recruiting | N/A | 15000 | Europe | non interventional study | Algalarrondo Vincent, Bichat Hospital, Bioquantis | Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis | 01/25 | 01/26 | | |
Tsai, Chon-Haw |
NCT03413384: To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia |
|
|
| Recruiting | 2 | 106 | RoW | Ceftriaxone, Ceftriaxone Sandoz powder for IV Injection, Placebo | BrainX Corporation, Virginia Contract Research Organization Co., Ltd. | Parkinson's Disease Dementia | 12/24 | 03/25 | | |
NCT04434768: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke |
|
|
| Recruiting | 1 | 14 | RoW | UMSC01 | Ever Supreme Bio Technology Co., Ltd. | Acute Stroke | 12/25 | 12/25 | | |
NCT05092243: Exploit the Functional Higher Neural Connectivity and Electrophysiological Intervention of Freezing of Gait in PD and PSP During Different Ambulatory Complexities |
|
|
| Recruiting | N/A | 40 | RoW | Transcranial direct current stimulation | China Medical University Hospital, Ministry of Science and Technology, Taiwan | Transcranial Direct Current Stimulation | 07/22 | 07/24 | | |
NCT06505460: Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study |
|
|
| Recruiting | N/A | 20 | RoW | Transcranial direct current stimulation | China Medical University Hospital, Ministry of Science and Technology, Taiwan | Transcranial Direct Current Stimulation | 07/25 | 07/27 | | |
Chen, Yeu-Chin |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
NCT05981274: A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A) |
|
|
| Recruiting | N/A | 45 | RoW | serum biomarker. | Tri-Service General Hospital | Severe Hemophilia A Without Inhibitor | 12/27 | 12/27 | | |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
Li, Gang |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
| Active, not recruiting | 4 | 948 | Europe, Canada, US, RoW | Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy | Population Health Research Institute | Intracranial Hemorrhages, Atrial Fibrillation | 04/26 | 10/26 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
| Completed | 3 | 2425 | RoW | urapidil, Intensive BP lowing | The George Institute for Global Health, China, Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China | Stroke, Acute, Cerebrovascular Disorders | 11/23 | 11/23 | | |
EAST, NCT06773364: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial |
|
|
| Not yet recruiting | 3 | 2423 | NA | Levetiracetam, Guide-recommended management, The lying flat (0°) head position, The sitting-up (≥30°) head position | Shanghai East Hospital | Suspected Stroke | 12/28 | 12/29 | | |
ATEM, NCT05416476: Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine |
|
|
| Recruiting | 3 | 288 | RoW | Anisodine Hydrobromide, Anisodine Hydrobromide placebo | Second Affiliated Hospital, School of Medicine, Zhejiang University | Migraine Without Aura, Migraine With Aura | 10/25 | 12/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Completed | 2 | 200 | RoW | Intravenous tirofiban combination therapy, Tirofiban | Shanghai East Hospital, Shanghai 6th People's Hospital, Ningbo No. 1 Hospital, Zhangzhou Municipal Hospital of Fujian Province, Shanghai 7th People's Hospital, Jinan Central Hospital, Xuchang Central Hospital | Ischemic Stroke | 07/23 | 10/23 | | |
PANDORA, NCT04995016: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 18 | RoW | Pembrolizumab, Keytruda, Axitinib, Inlyta | Tianjin Medical University Second Hospital | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | 08/22 | 08/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT04093336: Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients |
|
|
| Recruiting | 1/2 | 120 | RoW | human umbilical cord mesenchymal stem cells, Placebo, standardized treatment | Shanghai East Hospital | Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain | 12/24 | 12/24 | | |
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease |
|
|
| Recruiting | N/A | 360 | RoW | MicRNAs battery | Shanghai Mental Health Center | Alzheimer's Disease | 08/22 | 11/22 | | |
NCT06468436: Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients |
|
|
| Not yet recruiting | N/A | 1508 | RoW | Dexmedetomidine-Esketamine Combination, Dexmedetomidine hydrochloride, Esketamine hydrochloride, Dexmedetomidine | Peking University First Hospital, Peking University International Hospital, Tianjin Medical University General Hospital | Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium | 06/30 | 12/30 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
Ho, Ching-Liang |
NCT04169178: Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status |
|
|
| Recruiting | 1 | 98 | RoW | HLX55, HLX55 monoclonal antibody for Injection | Henlix, Inc | Solid Tumor, Adult | 12/22 | 12/22 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
NCT02347228: Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | OB318 capsule | Oneness Biotech Co., Ltd. | Advanced Solid Malignancies | 12/24 | 12/24 | | |
Khan, Sarah |
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor |
|
|
| Active, not recruiting | 3 | 250 | Canada, RoW | Ipatasertib, Fulvestrant, Placebo | Canadian Cancer Trials Group, Hoffmann-La Roche | Breast Cancer | 12/24 | 12/26 | | |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's |
|
|
| Recruiting | 2 | 180 | US | Placebo, Eligard 22.5Mg Suspension for Injection | Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals | Alzheimer Disease, Mild Cognitive Impairment | 12/25 | 02/26 | | |
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression |
|
|
| Recruiting | 2 | 324 | Europe | Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib | Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche | Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer | 09/26 | 09/26 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Recruiting | 1 | 45 | Europe | Palbociclib, Ibrance, Avelumab, Bavencio | Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now | Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer | 07/25 | 12/25 | | |
Dai, Ming-Shen |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients |
|
|
| Recruiting | 1/2 | 24 | RoW | donor-derived NK cell infusion | Precision Biotech Taiwan Corp., Tri-Service General Hospital | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
| Completed | 1/2 | 272 | Europe, Canada, Japan, US, RoW | Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 07/24 | 11/24 | | |
NCT05036486: The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer |
|
|
| Recruiting | N/A | 400 | RoW | next-generation sequencing | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital, Chang Gung Medical Foundation (Linkou Branch), Taipei Medical University Shuang Ho Hospital, Koo Foundation Sun Yat-Sen Cancer Center, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Chiayi, Taoyuan General Hospital, Ministry of Health and Welfare, Mackay Memorial Hospital | Biliary Tract Cancer (BTC) | 12/30 | 12/30 | | |
Chen, Hsiang-Cheng |
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) |
|
|
| Active, not recruiting | 3 | 292 | Europe, Japan, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 09/24 | 12/24 | | |
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) |
|
|
| Recruiting | 3 | 472 | Europe, Canada, US, RoW | TILD, matching placebo injections | Sun Pharmaceutical Industries Limited | Active Psoriatic Arthritis | 05/25 | 02/26 | | |
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus |
|
|
| Terminated | 2 | 85 | Europe, US, RoW | LY3361237, Placebo | Eli Lilly and Company | Systemic Lupus Erythematosus | 12/23 | 12/23 | | |
NCT05807529: A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis |
|
|
| Active, not recruiting | 1/2 | 136 | RoW | 2ccPA, 2-carba-cyclic phosphatidic acid, Placebo | Orient Europharma Co., Ltd. | Osteoarthritis, Knee | 12/24 | 12/24 | | |
Yeh, Chin-Bin |
NCT05974241: Irritability in Children With ADHD and Emotion Dysregulation |
|
|
| Completed | 4 | 36 | RoW | Methylphenidate, aripiprazole, and combination, Ritalin/Concerta, Abilify, and combination | Tri-Service General Hospital | Irritable Mood, ADHD | 04/22 | 04/22 | | |
NCT05043805: Dextromethorphan Added on for Children With Chronic Irritability |
|
|
| Enrolling by invitation | 4 | 120 | RoW | Dextromethorphan, regrow, placebo | Tri-Service General Hospital | Irritable Mood | 04/24 | 06/24 | | |
Chen, Yeu Chin |
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
|
|
| Recruiting | 3 | 733 | Europe, US, RoW | Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) | 07/29 | 07/29 | | |
Huang, Tzu-Chuan |
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer |
|
|
| Approved for marketing | N/A | | Europe, Canada, RoW | Abemaciclib, LY2835219 | Eli Lilly and Company | Metastatic Breast Cancer | | | | |
Dai, Min |
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty |
|
|
| Recruiting | 2 | 240 | RoW | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Suzhou Alphamab Co., Ltd. | Knee Arthroplasty, Total | 12/25 | 04/26 | | |
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients |
|
|
| Recruiting | 1/2 | 24 | RoW | donor-derived NK cell infusion | Precision Biotech Taiwan Corp., Tri-Service General Hospital | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
Ma, Hsin-I |
NCT03008148: Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM |
|
|
| Recruiting | 2/3 | 288 | RoW | CCRT, Temozolomide, Chemotherapy, Siroquine, JP001 | Johnpro Biotech, Inc. | Glioblastoma | 04/25 | 04/25 | | |
Lin, Wei-Hsiang |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
Lu, Chueng-He |
NCT05115955: PO Pain Management with Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery |
|
|
| Completed | 4 | 76 | RoW | DS group, NALDEBAIN®, Control group, Sesame oil | Tri-Service General Hospital | Anesthesiology, Orthopedic | 05/24 | 06/24 | | |
Hsu, Shiuh-Liang |
NCT06381986: Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients |
|
|
| Active, not recruiting | 2 | 122 | RoW | SHJ002, Vehicle | Sunhawk Vision Biotech, Inc. | Corneal Erosion | 01/25 | 02/25 | | |
Pan, Ru-Yu |
NCT05115955: PO Pain Management with Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery |
|
|
| Completed | 4 | 76 | RoW | DS group, NALDEBAIN®, Control group, Sesame oil | Tri-Service General Hospital | Anesthesiology, Orthopedic | 05/24 | 06/24 | | |
Pietrucha, Slavomir |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US, RoW | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
Bennys, Karim |
DARIDOR-ALZ, NCT05924425: Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease |
|
|
| Recruiting | 4 | 62 | Europe | Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, 24-hour Ambulatory Blood Pressure Monitoring (ABPM, Biomarker assay | University Hospital, Montpellier, Idorsia Pharmaceuticals Ltd. | Alzheimer Disease, Insomnia Disorder, Sleep | 05/26 | 03/27 | | |
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen, Biogen Idec Research Limited | Alzheimer's Disease | 08/24 | 08/24 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Completed | 2 | 72 | Europe | NanoLithium® NP03, Placebo | Medesis Pharma SA, MEDESIS Pharma SA | Alzheimer's Disease | 01/24 | 10/24 | | |
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age |
|
|
| Active, not recruiting | 2 | 416 | Europe, Canada, Japan, US, RoW | BIIB080, ISIS 814907, BIIB080-matching placebo | Biogen | Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia | 05/26 | 01/29 | | |
| Recruiting | N/A | 342 | Europe | Measurement of amyloid and pTau blood biomarkers | University Hospital, Montpellier | Alzheimer Disease, Mild Cognitive Impairment, Dementia, Tauopathies | 11/24 | 12/24 | | |
| Recruiting | N/A | 120 | Europe | Multiomics quantification, Polysomnography | University Hospital, Montpellier | Alzheimer Disease, Elderly With Normal Cognition | 04/24 | 01/26 | | |
COGNIKET-MCI, NCT06347315: Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment |
|
|
| Recruiting | N/A | 380 | Europe | BrainXpert, Placebo | Société des Produits Nestlé (SPN) | Mild Cognitive Impairment | 12/27 | 12/27 | | |
| Not yet recruiting | N/A | 120 | Europe | neuropsychologist interview, questionnaire | University Hospital, Montpellier, Laboratoire EPSYLON | Alzheimer Disease, Early Onset, Parkinsons Disease With Dementia, Non Pharmacological Intervention | 12/25 | 12/25 | | |
| Recruiting | N/A | 1000 | Europe | | University Hospital, Toulouse, France Alzheimer | Alzheimer Disease | 06/26 | 01/27 | | |
ALZ-OREX, NCT05629871: Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline? |
|
|
| Recruiting | N/A | 132 | Europe | Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetry, Fractional diuresis, Internal temperature measurement, Biomarker assay | University Hospital, Montpellier, Institut National de la Santé Et de la Recherche Médicale, France | Neuropathology | 07/27 | 07/27 | | |
| Not yet recruiting | N/A | 50 | NA | Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, Biomarker assay | University Hospital, Montpellier, Institut National de la Santé Et de la Recherche Médicale, France | Neuropathology, Cognitive Decline, Sleep Disorder | 08/27 | 12/27 | | |
yang, fu-chi |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
Wu, Yi-Ying |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
Lu, Chieh Hua |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
Shih, TungYuan Mr |
NCT05557448: To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose |
|
|
| Recruiting | 2 | 24 | RoW | TYNADOTE, Placebo Oral Tablet | Sinew Pharma Inc., Taipei Veterans General Hospital, Taiwan | Hepatitis | 12/26 | 12/26 | | |
NCT03451487: A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study |
|
|
| Completed | N/A | 28 | RoW | Panadol®, Acetaminophen, SafeTynadol®, SNP-810 | Sinew Pharma Inc. | Acetaminophen Toxicity | 12/22 | 12/22 | | |
NCT05563961: A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers |
|
|
| Recruiting | N/A | 48 | RoW | Panadol®, SafeTynadol® | Sinew Pharma Inc. | Hepatitis, Pharmacology | 06/24 | 12/24 | | |
Hsiong, ChengHuei Mr |
NCT05557448: To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose |
|
|
| Recruiting | 2 | 24 | RoW | TYNADOTE, Placebo Oral Tablet | Sinew Pharma Inc., Taipei Veterans General Hospital, Taiwan | Hepatitis | 12/26 | 12/26 | | |
NCT05563961: A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers |
|
|
| Recruiting | N/A | 48 | RoW | Panadol®, SafeTynadol® | Sinew Pharma Inc. | Hepatitis, Pharmacology | 06/24 | 12/24 | | |
Matus, Maria Guadalupe |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
Liao, Zhengluan |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
Chen, Yi-Hsien |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |